Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | STK39 | Q9UEW8 | 13/20 | 0.48 |
| ▸ | PARG | Q86W56 | 4/20 | 0.48 |
| ▸ | CTSD | P07339 | 2/20 | 0.44 |
| ▸ | PNLIP | P16233 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5301320 | 0.93 | PTGS1 (0.49) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL2296510 | 0.89 | TMPRSS4 (0.50) | — | |
| SCHEMBL5291854 | 0.88 | RAB9A (0.41) | — | |
| SCHEMBL2295353 | 0.85 | RAB9A (0.45) | PNLIP | |
| SCHEMBL2298615 | 0.84 | PTGDR2 (0.42) | — | |
| SCHEMBL2297485 | 0.84 | KMT2A (0.47) | — | |
| SCHEMBL2297522 | 0.83 | RAB9A (0.44) | — | |
| SCHEMBL2295816 | 0.83 | RAB9A (0.45) | — | |
| SCHEMBL2297569 | 0.83 | TMPRSS4 (0.49) | — | |
| SCHEMBL2295674 | 0.83 | NPC1 (0.56) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |